Two different types of bills advanced through a pair of state legislatures late last week, a pointed reminder to the pharmaceutical industry that its business practices will continue to encounter significant pushback.
In Nevada, the state Senate overwhelming approved legislation that is designed to lower the cost of diabetes medicines by requiring drug makers to report pricing histories, disclose costs, and notify state officials and insurers in advance of price hikes above inflation. An assembly hearing is now expected to occur this week, according to state Senator Yvanna Cancela, who introduced the bill.
About the Author Reprints
